We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




CSF Glucose Unaltered in Patients With Dementia

By LabMedica International staff writers
Posted on 14 Dec 2022
Print article
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)

A plethora of the pathological processes of many dementia disorders begin several years before the clinical expression of the diseases, and for that reason it is important to discover new biomarkers and methods to detect these processes at an early stage.

Glucose is transported from the blood, through the blood brain barrier (BBB), and into the interstitial space, where it is made available for metabolism by astrocytes and neurons. Normally, there is a close relationship between cerebrospinal fluid (CSF) and plasma glucose concentrations, and the ratio ranges between 0.5 and 0.8, but the ratio may change in different pathological conditions.

Clinical Scientists at the Copenhagen University Hospital Rigshospitalet (Copenhagen, Denmark) and their colleagues collected CSF and plasma samples from patients referred for diagnostic evaluation. The samples were taken from 446 patients (Alzheimer’s Disease (AD) (n=320), vascular dementia (VaD) (n=64), frontotemporal dementia (FTD) (n=27) and dementia with Lewy bodies (DLB) (n=35)), and 130 healthy controls (HC) (healthy subjects (HS) (n=34), non-demented HS (n=96)).

CSF was collected in 5 mL polypropylene tubes, transported at room temperature, and analyzed on a Radiometer ABL instrument (Radiometer Medical ApS, Brønshøj, Denmark) within an hour after sampling. Plasma was collected in 2 mL Greiner bio-one VACUETTE tubes with Sodium Fluoride/Potassium Oxalate (Greiner, Kremsmünster, Austria), transported at room temperature, and analyzed on a COBAS 8000 instrument (Roche Diagnostics, Indianapolis, IN, USA) within three hours after sampling.

The investigators reported that no significant differences in CSF and plasma glucose levels between the dementia group and HC were found. Furthermore, no significant difference in the CSF/plasma glucose ratio was identified. When investigating CSF glucose, plasma glucose and the CSF/plasma glucose ratio for the different etiologies within the dementia group, no significant differences were found. In addition, no statistically significant differences were found in the relationship between age and CSF glucose, plasma glucose and the CSF/plasma glucose ratio.

The authors concluded that despite severe reductions in the glucose metabolism in the brain of patients with dementia disorders, CSF and plasma glucose levels and the CSF/plasma-glucose ratio do not reflect this hypometabolism, and do not differentiate between dementia of different etiologies. For that reason, it is unlikely that they will have diagnostic potential in a mixed memory clinic setting. The study was published on December 8. 2022 in the journal Clinical Biochemistry.

Related Links:
Copenhagen University Hospital Rigshospitalet
Radiometer Medical
Greiner
Roche Diagnostics

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
QC Software Solution
Unity Interlaboratory Program

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.